Effects of progesterone and its antagonist mifepristone on progesterone receptor a expression in human umbilical vein endothelial cells

Gynecologic and Obstetric Investigation

Volumn 67, Issue 4, 2009, Pages 269-274

  Toth, Bettina ^a   Scholz, Christoph ^b   Ochsenkühn, Robert ^a   Schulze, Sandra ^b   Kuhn, Christina ^b   Friese, Klaus ^a,b   Jeschke, Udo ^b  

^a Department of Obstetrics and Gynecology Grosshadern ^*  (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Human umbilical vein endothelial cells; Progesterone receptor A and B; Progesterone receptor antagonist

Indexed keywords

ESTROGEN RECEPTOR BETA; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR A;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MIFEPRISTONE; PROGESTERONE; RECEPTORS, PROGESTERONE; UMBILICAL VEINS;

EID: 63349096720     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210373     Document Type: Article

References (30)

1. Feletou M, Vanhoutte PM: Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 291:H985-H1002.
2. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A: Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28: 576-582.
3. Herrington D: Role of estrogens, selective estrogen receptor modulators and phytoestrogens in cardiovascular protection. Can J Cardiol 20 00; 16(suppl E):5E-9E.
4. Kublickiene K, Svedas E, Landgren BM, Crisby M, Nahar N, Nisell H, Poston L: Small artery endothelial dysfunction in postmeno-pausal women: in vitro function, morphology, and modification by estrogen a nd selective estrogen receptor modulators. J Clin Endocrinol Metab 2005; 90: 6113-6122.
5. Majmudar NG, Robson SC, Ford GA: Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab 2000; 85: 1577-1583.
6. Kannel WB: The Framingham study. BMJ 1976; 2: 1255.
7. Low AK, Russell LD, Holman HE, Shepherd JM, Hicks GS, Brown CA: Hormone replacement therapy and coronary heart disease in women: a review of the evidence. Am J Med Sci 2002; 324:180-184.
8. Gouva L, Tsatsoulis A: The role of estrogens in cardiovascular disease in the aftermath of clinical trials. Hormones (Athens) 2004; 3: 171-18 3.
9. Rosano GM, Vitale C, Fini M: Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann NY Acad Sci 2006; 1092:341-348.
10. Rossouw JE, Anderson GL, Prentice RL, La-Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
11. Lemay A: The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 2002; 24: 711- 715.
12. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991; 265:1861-1867.
13. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-534.
14. Tannen RL, Weiner MG, Xie D, Barnhart K: A simulation using data from a primary care practice database closely replicated the women's health initiative trial. J Clin Epidemiol 2007; 60:686-695.
15. Sharma S: Hormone replacement therapy in menopause: current concerns and considerations. Kathmandu Univ Med J 2003; 1: 288- 293.
16. Tansavatdi K, McClain B, Herrington DM: The effects of smoking on estradiol metabolism. Minerva Ginecol 2004; 56:105-114.
17. Bagchi D, Das DK, Tosaki A, Bagchi M, Ko-thari SC: Benefits of resveratrol in women's hea lth. Drugs Exp Clin Res 2001; 27: 233- 248.
18. Dhiman RK, Chawla YK: Is there a link between oestrogen therapy and gallbladder disease? Expert Opin Drug Saf 2006; 5:117- 129.
19. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heck-bert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R: Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357-365.
20. Vickers MR, Martin J, Meade TW: The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health 2007; 7:2.
21. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR: Differential signal transduction of progesterone and medroxyprogester-one acetate in human endothelial cells. En-docrinolog y 2004; 145: 5745-5756.
22. Adams MR, Clarkson TB, Shively CA, Parks JS, Kaplan JR: Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol 1990; 163:1388-1393.
23. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:217-221.
24. Nilsen J, Brinton RD: Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 2003; 100:10506-10511.
25. Toth B, Saadat G, Geller A, Scholz C, Schulze S, Friese K, Jeschke U: Human umbilical vascular endothelial cells express estrogen receptor beta (ERbeta) and progesterone receptor A (PR-A), but not ERalpha and PR-B. Histochem Cell Biol 2008; 130:399-405.
26. Fu XD, Flamini M, Sanchez AM, Goglia L, Giretti MS, Genazzani AR, Simoncini T: Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod 2008; 14: 225-234.
27. Hermenegildo C, Oviedo PJ, Garcia-Perez MA, Tarin JJ, Cano A: Effects of phytoestrogens genistein and daidzein on prostacyclin production by human endothelial cells. J Pharmacol Exp Ther 2005; 315: 722-728.
28. Tatsumi H, Kitawaki J, Tanaka K, Hosoda T, Honjo H: Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins. Maturitas 2002; 42:287-294.
29. Simoncini T, Caruso A, Giretti MS, Scorticat i C, Fu XD, Garibaldi S, Baldacci C, Mannella P, Fornari L, Genazzani AR: Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006; 86(suppl 4):1235-1242.
30. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB: Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase viaglucocorticoid receptors. FASEB J 2007; 21:265-273.